Ideaya Biosciences granted fast track designation for darovasertib

Ideaya Biosciences announced that the FDA has granted fast track designation to Ideaya’s development program investigating darovasertib, a potential first-in-class protein kinase C, or PKC, inhibitor, for use in combination with crizotinib, an investigational cMET inhibitor, for the treatment of adult patients with metastatic uveal melanoma.